|
| 37832831 | Percutaneous Image Guided Cryoablation of Adrenal Metastases From Renal Cell Carcinoma: A Single Institution Review. | Urology | 2024 |
| 36067373 | Cost-effectiveness of Adjuvant Pembrolizumab After Nephrectomy for High-risk Renal Cell Carcinoma: Insights for Patient Selection From a Markov Model. | J Urol | 2023 |
| 37193610 | Outcomes of Second-Line Therapies in Patients With Metastatic de Novo and Treatment-Emergent Neuroendocrine Prostate Cancer: A Multi-Institutional Study. | Clin Genitourin Cancer | 2023 |
| 37051531 | Development and validation of a unifying pre-treatment decision tool for intracranial and extracranial metastasis-directed radiotherapy. | Front Oncol | 2023 |
| 37414595 | Circulating antigen-primed cytotoxic T-cells in patients with renal tumors treated with surgery. | Urol Oncol | 2023 |
| 36924119 | Dynamic assessment of serum chromogranin A and treatment response with abiraterone acetate in metastatic castration-resistant prostate cancer. | Prostate | 2023 |
| 36745503 | Antibody-Based Therapeutics for the Treatment of Renal Cell Carcinoma: Challenges and Opportunities. | Oncologist | 2023 |
| 36509653 | International Multi-institutional Characterization of the Perioperative Morbidity of Metastasectomy for Renal Cell Carcinoma. | Eur Urol Oncol | 2023 |
| 36571507 | Development and validation of a recursive partitioning analysis-based pretreatment decision-making tool identifying ideal candidates for spine stereotactic body radiation therapy. | Cancer | 2023 |
| 34364796 | A Prospective Multicenter Evaluation of Initial Treatment Choice in Metastatic Renal Cell Carcinoma Prior to the Immunotherapy Era: The MaRCC Registry Experience. | Clin Genitourin Cancer | 2022 |
| 35641216 | Rational Second-Generation Antiandrogen Use in Prostate Cancer. | Oncologist | 2022 |
| 35751046 | Evaluation of PD-L1 and B7-H3 expression as a predictor of response to adjuvant chemotherapy in bladder cancer. | BMC Urol | 2022 |
| 35878715 | Radiation Therapy in Oligometastatic Prostate Cancer. | Int J Radiat Oncol Biol Phys | 2022 |
| 36251574 | Comparative cost-effectiveness of neoadjuvant chemotherapy regimens for muscle-invasive bladder cancer: Results according to VESPER data. | Cancer | 2022 |
| 35151922 | Development and Internal Validation of a Recursive Partitioning Analysis-Based Model Predictive of Pain Flare Incidence After Spine Stereotactic Body Radiation Therapy. | Pract Radiat Oncol | 2022 |
| 34876376 | Thoracic Radiotherapy for Renal Cell Carcinoma Metastases: Local Control for the Management of Lung and Mediastinal Disease in the Modern Era. | Clin Genitourin Cancer | 2022 |
| 35084429 | Development and Assessment of a Predictive Score for Vertebral Compression Fracture After Stereotactic Body Radiation Therapy for Spinal Metastases. | JAMA Oncol | 2022 |
| 34991070 | Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. | J Natl Compr Canc Netw | 2022 |
| 35168879 | Outcomes following cytoreductive nephrectomy without immediate postoperative systemic therapy for patients with synchronous metastatic renal cell carcinoma. | Urol Oncol | 2022 |
| 35261092 | Midwest rural-urban disparities in use of patient online services for COVID-19. | J Rural Health | 2022 |
| 34862099 | A Clinical Decision Aid to Support Personalized Treatment Selection for Patients with Clinical T1 Renal Masses: Results from a Multi-institutional Competing-risks Analysis. | Eur Urol | 2022 |
| 34515877 | Phase I study of cediranib, an oral VEGFR inhibitor, in combination with selumetinib, an oral MEK inhibitor, in patients with advanced solid malignancies. | Invest New Drugs | 2022 |
| 34750052 | Collecting duct carcinoma: A single-institution retrospective study. | Urol Oncol | 2022 |
| 34294873 | Differential impact of tumor suppressor gene (TP53, PTEN, RB1) alterations and treatment outcomes in metastatic, hormone-sensitive prostate cancer. | Prostate Cancer Prostatic Dis | 2022 |
| 32500206 | Cisplatin-associated neuropathy characteristics compared with those associated with other neurotoxic chemotherapy agents (Alliance A151724). | Support Care Cancer | 2021 |
| 35720756 | A Scalable Framework for Telehealth: The Mayo Clinic Center for Connected Care Response to the COVID-19 Pandemic. | Telemed Rep | 2021 |
| 33765337 | Active surveillance of metastatic renal cell carcinoma: Results from a prospective observational study (MaRCC). | Cancer | 2021 |
| 33824031 | A Living, Interactive Systematic Review and Network Meta-analysis of First-line Treatment of Metastatic Renal Cell Carcinoma. | Eur Urol | 2021 |
| 33673926 | 40-Year-Old Man With Left Leg Swelling and Abdominal Pain. | Mayo Clin Proc | 2021 |
| 33583072 | Leucine Zipper 4 Autoantibody: A Novel Germ Cell Tumor and Paraneoplastic Biomarker. | Ann Neurol | 2021 |
| 33798590 | Assessment of isochromosome 12p and 12p abnormalities in germ cell tumors using fluorescence in situ hybridization, single-nucleotide polymorphism arrays, and next-generation sequencing/mate-pair sequencing. | Hum Pathol | 2021 |
| 35041344 | Phase II Trial of Bevacizumab Monotherapy in Pancreatic Neuroendocrine Tumors. | Pancreas | 2021 |
| 34480623 | Correction to: Cisplatin-associated neuropathy characteristics compared with those associated with other neurotoxic chemotherapy agents (Alliance A151724). | Support Care Cancer | 2021 |
| 34593526 | Phase II Evaluation of Stereotactic Ablative Radiotherapy (SABR) and Immunity in <sup>11</sup>C-Choline-PET/CT-Identified Oligometastatic Castration-Resistant Prostate Cancer. | Clin Cancer Res | 2021 |
| 33990538 | Tumor- and osteoclast-derived NRP2 in prostate cancer bone metastases. | Bone Res | 2021 |
| 34232950 | Chemoimmunotherapy after progression on single-agent pembrolizumab for metastatic urothelial carcinoma: a case series. | Anticancer Drugs | 2021 |
| 34254332 | Chemotherapy with atezolizumab for small cell or neuroendocrine carcinoma of the prostate: A single institution experience. | Prostate | 2021 |
| 31393812 | Complete Surgical Metastasectomy of Renal Cell Carcinoma in the Post-Cytokine Era. | J Urol | 2020 |
| 31661374 | Reply by Authors. | J Urol | 2020 |
| 31829518 | Concordance of PD-1 and PD-L1 (B7-H1) in paired primary and metastatic clear cell renal cell carcinoma. | Cancer Med | 2020 |
| 31761613 | The association of anxiety and depression with perioperative and oncologic outcomes among patients with clear cell renal cell carcinoma undergoing nephrectomy. | Urol Oncol | 2020 |
| 33121461 | 8q24 clear cell renal cell carcinoma germline variant is associated with VHL mutation status and clinical aggressiveness. | BMC Urol | 2020 |
| 32469396 | Evaluation of the Safety and Efficacy of Immunotherapy Rechallenge in Patients With Renal Cell Carcinoma. | JAMA Oncol | 2020 |
| 32489901 | Penile cancer with visceral metastasis and p16/human papillomavirus positivity: An unusual case of long-term survival. | Urol Case Rep | 2020 |
| 30837548 | Shared and unique genomic structural variants of different histological components within testicular germ cell tumours identified with mate pair sequencing. | Sci Rep | 2019 |
| 31693980 | NCCN Guidelines Insights: Kidney Cancer, Version 2.2020. | J Natl Compr Canc Netw | 2019 |
| 29069303 | A prospective genome-wide study of prostate cancer metastases reveals association of wnt pathway activation and increased cell cycle proliferation with primary resistance to abiraterone acetate-prednisone. | Ann Oncol | 2018 |
| 29858590 | Serum chromogranin-A-based prognosis in metastatic castration-resistant prostate cancer. | Prostate Cancer Prostatic Dis | 2018 |
| 30017400 | The Probability of Aggressive Versus Indolent Histology Based on Renal Tumor Size: Implications for Surveillance and Treatment. | Eur Urol | 2018 |
| 30228096 | Risk prediction models for cancer-specific survival following cytoreductive nephrectomy in the contemporary era. | Urol Oncol | 2018 |